+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 89 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
R

Actively Recruiting

Researchers are evaluating tulisokibart as a treatment for radiographic axial spondyloarthritis r-axSpA, a type of arthritis causing pain, stiffness, and inflammation in the spine and pelvis joints. This condition leads to damage visible on X-rays. The study aims to find out if different doses of tulisokibart improve symptoms better than a placebo, which looks like the medicine but contains no active drug. Participants will be assigned to one of four groups a high dose, medium dose, low dose of tulisokibart, or a placebo. After 16 weeks, those on the low dose or placebo will be randomly reassigned to receive either the medium or high dose. The study includes a 16-week placebo-controlled period followed by a 124-week long-term extension, which consists of a 40-week main extension and an 84-week optional extension. Tulisokibart is given through subcutaneous injections. During the study, participants will undergo assessments of their arthritis symptoms using various scales and imaging, including MRI scans of the spine and pelvis. Researchers will monitor changes in pain, function, disease activity, and fatigue at baseline and after 16 weeks. Safety will be tracked throughout the study and for up to about 154 weeks. The study is scheduled to complete in early 2030.

Age: 18Years - 80YearsAll GendersPhase 2
107 locations
E

Actively Recruiting

Researchers are evaluating the safety, optimal dose, and effectiveness of a combination treatment involving BNT323 trastuzumab pamirtecan and BNT327 pumitamig in people with advanced breast cancer. This includes patients with hormone receptor-positive or negative, HER2-positive, HER2-low, HER2-ultralow, HER2-null breast cancer, or triple-negative breast cancer. The study is a Phase III, multi-site, open-label trial designed to find the best dose and assess the treatments effects in these groups. The study has two parts. Part 1 involves dose escalation where participants with chemotherapy-pretreated advanced breast cancer receive various dose levels of BNT323 plus BNT327 to determine the recommended Phase 2 dose. Part 2 includes dose optimization and exploratory groups, beginning after Part 1s completion. In Part 2 Cohort 1, participants are randomized into four arms to receive either the combination at the recommended dose, the combination at another dose, BNT323 alone, or BNT327 alone. Other cohorts receive the recommended dose without randomization. Participants will undergo treatment cycles with intravenous infusions of the study drugs and be monitored for safety, side effects, and tumor response for up to 36 months. Assessments include tracking dose-limiting toxicities, adverse events, tumor scans, and response rates. Safety monitoring continues up to 90 days after the last dose. The study aims to provide detailed information on the best dose, safety, and potential benefits of these treatments for advanced breast cancer.

Age: 18Years +All GendersPhase 1Phase 2
81 locations
E

Actively Recruiting

Researchers are studying the effectiveness, safety, and tolerability of combining elecoglipron and dapagliflozin compared to using each drug alone in adults with type 2 diabetes mellitus T2DM who are not well controlled by lifestyle changes or other diabetes medications. This phase III trial aims to understand how well these treatments manage blood sugar levels in this population. Participants will be randomly assigned to one of five groups two different doses of elecoglipron combined with dapagliflozin, two doses of elecoglipron combined with a placebo matching dapagliflozin, or dapagliflozin alone with a placebo matching elecoglipron. All medications are taken orally once daily. The study uses a double-blind, parallel-group design to compare these treatments over 40 weeks. During the study, participants will have their blood sugar control measured primarily by changes in Hemoglobin A1c HbA1c from the start to week 40. Secondary measures include body weight changes, fasting plasma glucose, blood pressure, and time to starting rescue medication. Regular assessments will monitor safety and treatment effects throughout the trial period, which lasts about 40 weeks.

Age: 18Years +All GendersPhase 3
303 locations
R

Actively Recruiting

The trial investigates treatments for adults with KRASNRAS and BRAF wild-type recurrent, unresectable, or metastatic colorectal cancer who have previously undergone chemotherapy. It compares how long participants live without disease progression and overall survival when treated with two different combinations of chemotherapy and targeted biological agents. This phase 3 study explores differences in outcomes between the use of amivantamab plus FOLFIRI chemotherapy and cetuximab or bevacizumab plus FOLFIRI chemotherapy. Participants are randomly assigned to one of two groups. One group receives amivantamab together with FOLFIRI, a chemotherapy regimen including 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan. The other group receives either cetuximab or bevacizumab with the same FOLFIRI chemotherapy. Treatments are given in 28-day cycles and continue until disease progression is observed on scans or other stopping criteria are met. During the study, participants undergo regular monitoring including radiographic scans to assess disease status and progression-free survival for up to 2 years and overall survival for over 4 years. Researchers also evaluate tumor response rates, duration and time to response, quality of life through questionnaires, side effects, and laboratory tests. The total study duration may extend up to more than 4 years to thoroughly assess treatment outcomes and safety.

Age: 18Years +All GendersPhase 3
251 locations
R

Actively Recruiting

This clinical trial is designed to compare the duration participants remain free of disease progression when treated with two different combinations of therapies for adults with KRASNRAS and BRAF wild-type unresectable or metastatic left-sided colorectal cancer. The study focuses on how amivantamab combined with chemotherapy compares to cetuximab combined with chemotherapy in treating this specific cancer type. Participants will be divided into two groups. One group receives amivantamab combined with chemotherapy, either mFOLFOX6 containing 5-fluorouracil, leucovorin calcium or levoleucovorin, and oxaliplatin or FOLFIRI containing 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan hydrochloride. The other group receives cetuximab combined with the same chemotherapy options. Treatments are given in 28-day cycles and continue until the cancer progresses or other reasons require stopping the treatment. Throughout the study, participants will undergo regular evaluations to monitor how long they remain without disease progression, assessed by independent review and investigators. Other assessments include overall survival, response rates, duration of response, quality of life questionnaires, and safety monitoring up to several years. The study spans several years, with primary outcomes measured up to over four years and additional follow-up extending beyond seven years to gather comprehensive data on treatment effects and patient well-being.

Age: 18Years +All GendersPhase 3
239 locations
E

Actively Recruiting

Immunoglobulin A nephropathy IgAN is a kidney disease where immune system proteins build up in the kidneys causing inflammation. This inflammation may lead to kidney damage over time and reduce kidney function. The study is evaluating how well mezagitamab changes protein levels in the urine compared to a placebo in adults with primary IgAN. It also aims to assess the safety and tolerability of mezagitamab and how it maintains kidney function long term compared to placebo. Participants are randomly assigned to one of two groups in the main study two-thirds will receive mezagitamab injections and one-third will receive placebo injections, both given subcutaneously for about 22 weeks. Additionally, an open-label group includes participants with varying protein levels or kidney function who receive mezagitamab similarly. The entire study lasts about 2 years, with treatment for 22 weeks followed by approximately 1.5 years of observation. During the study, participants will have regular clinic visits, including monthly check-ups during the observation period. Assessments include measuring changes in urine protein levels and kidney function over time. Safety and tolerability of the study drug will also be monitored throughout the trial. Participants may continue in the study for up to 104 weeks, with ongoing evaluations to track kidney health and proteinuria.

Age: 18Years +All GendersPhase 3
186 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of nipocalimab compared to placebo in adults with moderate to severe systemic lupus erythematosus SLE, a long-term autoimmune disease where the immune system attacks healthy tissues causing inflammation in various organs. This phase 3, randomized, double-blind study aims to determine how well nipocalimab works alongside standard care treatments in managing SLE symptoms and disease activity. Participants will receive either nipocalimab or placebo combined with standard care treatments during a 52-week double-blind period. After this, eligible participants from both groups can join an open-label extension where they will continue to receive nipocalimab until Week 156 or until the study intervention is stopped. This design allows comparison of nipocalimabs effects versus placebo and longer-term safety and effectiveness in an open-label setting. Throughout the study, participants undergo regular assessments including disease activity indexes, joint evaluations, and fatigue scores. Researchers will track the percentage of participants achieving a standard SLE response measure at Week 52 and monitor changes in oral glucocorticoid use, joint pain, and flare-free status. Safety and treatment adherence are closely monitored across study visits, with data collected up to 3 years for long-term evaluation.

Age: 18Years - 75YearsAll GendersPhase 3
272 locations
G

Actively Recruiting

Researchers are studying the efficacy and safety of rilvegostomig combined with gemcitabine plus cisplatin compared to durvalumab combined with the same chemotherapy as first-line treatment for patients with advanced biliary tract cancer BTC. This Phase III, randomized, open-label study aims to evaluate these treatments in patients with unresectable locally advanced or metastatic BTC, including intra-hepatic or extra-hepatic cholangiocarcinoma and gallbladder carcinoma. Participants receive either rilvegostomig or durvalumab intravenously, both alongside gemcitabine and cisplatin chemotherapy. Durvalumab is given at 1500 mg IV every 3 weeks for up to 8 cycles, then every 4 weeks. Rilvegostomig is administered IV every 3 weeks. The chemotherapy regimen consists of gemcitabine 1000 mgm2 plus cisplatin 25 mgm2 on Day 1 and Day 8 of each 21-day cycle. Treatment continues according to the study protocol with close monitoring. During the study, participants undergo assessments including tumor measurements by CT or MRI using RECIST 1.1 criteria, evaluation of PD-L1 status, and performance status checks. Researchers also monitor overall survival and progression-free survival for up to approximately four years, as well as safety, tolerability, pharmacokinetics, and patient-reported symptoms and quality of life. Follow-up continues up to 12 weeks after disease progression for additional evaluations.

Age: 18Years +All GendersPhase 3
183 locations
S

Actively Recruiting

Researchers are evaluating zolbetuximab combined with pembrolizumab and chemotherapy in adults with stomach cancer or gastroesophageal junction GEJ cancer that is HER2-negative, Claudin 18.2-positive, and PD-L1-positive. The study focuses on people with locally advanced unresectable or metastatic disease who may have had prior standard treatments. This phase 3 randomized, double-blind study aims to understand how well zolbetuximab works with other therapies compared to placebo with pembrolizumab and chemotherapy. Participants receive either zolbetuximab or placebo intravenously every 2 or 3 weeks, along with pembrolizumab infusions every 3 or 6 weeks. Chemotherapy is given as either CAPOX oral capecitabine tablets and oxaliplatin infusions or mFOLFOX6 infusions of oxaliplatin, folinic acid, and 5-fluorouracil over several cycles. Treatment continues until cancer progression, intolerable side effects, or another cancer therapy is needed. Pembrolizumab may be given for up to 2 years. During the study, participants visit clinics for treatment infusions, health checks, and scans to monitor cancer changes. Medical problems and side effects are tracked, and tumor samples may be collected if treatment stops due to progression. Follow-up visits and telephone health checks continue after treatment to monitor participants health and cancer status. The study measures overall survival as the main outcome over up to 72 months.

Age: 18Years +All GendersPhase 3
252 locations

1-10 of 89

1